CONFERENCE •

Intravacc and Celonic to develop and produce a novel COVID-19 vaccine • Combining Intravacc’s OMV-delivery platform with Covid-19 Spike proteins • Preclinical studies to start shortly for candidate selection and inhouse pilot scale GMP production

SEMINAR •

Intravacc to in-license CimCure’s iBoost technology, expanding its vaccine platform portfolio * iBoost technology well suited for developing cancer vaccines * Joint development of Covid-19 vaccine using

SEMINAR •

Intravacc and Leiden University developed an animal replacement method for vaccines. • Need for alternatives to animal testing in quality control of vaccines • Inactivation of vaccines can be traced without using laboratory animals.

CONFERENCE •

Intravacc and Celonic to develop and produce a novel COVID-19 vaccine • Combining Intravacc’s OMV-delivery platform with Covid-19 Spike proteins • Preclinical studies to start shortly for candidate selection and inhouse pilot scale GMP production

CONFERENCE •

Intravacc to in-license CimCure’s iBoost technology, expanding its vaccine platform portfolio * iBoost technology well suited for developing cancer vaccines * Joint development of Covid-19 vaccine using iBoost

SEMINAR •

Intravacc and Leiden University developed an animal replacement method for vaccines. • Need for alternatives to animal testing in quality control of vaccines • Inactivation of vaccines can be traced without using laboratory animals.

CONFERENCE •

Intravacc and Celonic to develop and produce a novel COVID-19 vaccine • Combining Intravacc’s OMV-delivery platform with Covid-19 Spike proteins • Preclinical studies to start shortly for candidate selection and inhouse pilot scale GMP production